Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2882258 | 1.00 | HTR1A (0.55) | HTR1A | |
| SCHEMBL14198662 | 1.00 | HTR1A (0.55) | HTR1A | |
| SCHEMBL8010266 | 0.80 | HTR1A (0.55) | HTR1A | |
| SCHEMBL13632840 | 0.80 | HTR1A (0.55) | HTR1A | |
| Hydrochloric Acid SCHEMBL4633314 | 0.79 | HTR1A (0.60) | HTR1A | |
| SCHEMBL8013988 | 0.78 | DRD2 (0.63) | HTR1A | |
| SCHEMBL14262563 | 0.78 | ADRB1 (0.56) | HTR1A | |
| SCHEMBL14262669 | 0.78 | ADRB1 (0.56) | HTR1A | |
| SCHEMBL4975881 | 0.77 | ADRB1 (0.55) | HTR1A | |
| SCHEMBL4975887 | 0.77 | ADRB1 (0.55) | HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730139-A2 | PHARMACEUTICAL DOSAGE FORMS AND COMPOSITIONS OF 5-HT1A RECEPTOR ANTAGONISTS | Wyeth (US) | 2006-12-13 | — | — | EP | claimed |
| WO-2005092307-A2 | PHARMACEUTICAL DOSAGE FORMS AND COMPOSITIONS OF 5-HT1A RECEPTOR ANTAGONISTS | WYETH (US) | 2005-10-06 | — | — | WO | claimed |
| US-20050215561-A1 | Pharmaceutical dosage forms and compositions | WYETH LLC | 2005-09-29 | — | — | US | claimed |
| US-7816362-B2 | Serotonergic agents | WYETH LLC (US) | 2010-10-19 | — | — | US | disclosed |
| US-20090215794-A1 | SEROTONERGIC AGENTS | WYETH (US) | 2009-08-27 | — | — | US | disclosed |
| EP-1971337-A1 | SEROTONERGIC AGENTS FOR TREATING SEXUAL DYSFUNCTION | Wyeth a Corporation of the State of Delaware (US) | 2008-09-24 | — | — | EP | disclosed |
| US-7425558-B2 | -4-substituted-N-(2-(4-(2,3-dihydro-benzo(1,4)dioxin-5-yl)-piperazin -1-yl)propy l)-N-pyridin-2-yl-benzamide or salts; 5-HT1A receptor antagonists; urinary incontinence | WYETH (US) | 2008-09-16 | — | — | US | disclosed |
| EP-1928863-A2 | PHARMACEUTICAL DOSAGE FORMS AND COMPOSITIONS COMPRISING LECOZTAN | Wyeth a Corporation of the State of Delaware (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20080070925-A1 | SEROTONERGIC AGENTS FOR TREATING SEXUAL DYSFUNCTION | WYETH LLC | 2008-03-20 | — | — | US | disclosed |
| WO-2007081374-A1 | SEROTONERGIC AGENTS FOR TREATING SEXUAL DYSFUNCTION | WYETH (US) | 2007-07-19 | — | — | WO | disclosed |
| US-20070099931-A1 | Pharmaceutical dosage forms and compositions | WYETH (US) | 2007-05-03 | — | — | US | disclosed |
| US-20050215561-A1 | Pharmaceutical dosage forms and compositions | WYETH LLC | 2005-09-29 | — | — | US | disclosed |
| EP-1339406-B1 | PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE FOR TREATING CENTRAL NERVOUS SYSTEM (CNS) DISORDERS | WYETH CORP (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20030216408-A1 | Serotonergic agents | WYETH | 2003-11-20 | — | — | US | disclosed |
| EP-1339406-A2 | PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE FOR TREATING CENTRAL NERVOUS SYSTEM (CNS) DISORDERS | Wyeth (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6586436-B2 | 4-(Cyano,nitro,trifluoromethyl or halogen)-N-(2-(4-(2,3-dihydro-benzo(1,4)dioxin-5-yl)-piperazin-1-yl)-propyl)-N-pyridin-2-yl-benzamide; central nervous system disorders | WYETH | 2003-07-01 | — | — | US | disclosed |
| US-20030022901-A1 | Serotonergic agents | WYETH | 2003-01-30 | — | — | US | disclosed |
| US-6469007-B2 | P-SUBSTITUTED-N-(2-(4-(2,3-DIHYDRO-BENZO(1,4)DIOXIN-5-YL) -PIPERAZIN-1-YL)-PROPYL)-N-PYRIDIN-2-YL-BENZAMIDE, | WYETH | 2002-10-22 | — | — | US | disclosed |
| US-20020107254-A1 | P-substituted-N-(2-(4-(2,3-dihydro-benzo(1,4)dioxin-5-yl) -piperazin-1-yl)-propyl)-N-pyridin-2-yl-benzamide, | AMERICAN HOME PRODUCTS CORPORATION | 2002-08-08 | — | — | US | disclosed |
| WO-2002044142-A2 | PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE FOR TREATING CENTRAL NERVOUS SYSTEM (CNS) DISORDERS | WYETH (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107254-A1 | P-substituted-N-(2-(4-(2,3-dihydro-benzo(1,4)dioxin-5-yl) -piperazin-1-yl)-propyl)-N-pyridin-2-yl-benzamide, | HTR1A, HTR1D, HTR2A | HTR1A 1/4885 |
| US-20030216408-A1 | Serotonergic agents | HTR1A, HTR1D, TPH1 | HTR1A 1/4885 |
| US-20070099931-A1 | Pharmaceutical dosage forms and compositions | CYP4B1, CYP1B1, CFTR | HTR1A 533/4885 |
| US-20050215561-A1 | Pharmaceutical dosage forms and compositions | CFTR, CYP4B1, CYP1B1 | HTR1A 616/4885 |
| US-20090215794-A1 | SEROTONERGIC AGENTS | HTR5A, HTR1A, HTR3A | HTR1A 2/4885 |
| US-20080070925-A1 | SEROTONERGIC AGENTS FOR TREATING SEXUAL DYSFUNCTION | HTR5A, HTR1A, HTR3A | HTR1A 2/4885 |
| US-20030022901-A1 | Serotonergic agents | HTR1A, HTR1D, TPH1 | HTR1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.